Indication

Skin and nail infections due to dermatophytes, yeasts and other fungi such as:, Tinea capitis, corporis, manuum, pedis, barbae, cruris, unguium or onychomycosis, Pityriasis versicolor, candidiasis of skin and nails, stomatitis angularis, otitis externa, mycoses secondarily infected with bacteria.

Adult Dose

Topical/Cutaneous\r\nAdult: \r\nTinea cruris, corporis & cutaneous canidiasis: Apply to affected area BID for 2 weeks\r\n\r\nTinea versicolor: Apply once daily to affected area for 2 weeks\r\n\r\nTinea pedis: Apply BID to affected area for 4 weeks

Child Dose

Tinea\r\n<2 years: Safety and efficacy not established\r\n\r\n>2 years: Apply BID for up to 1 month

Contraindication

History of sensitivity reactions to Miconazole or any of the components of the preparation.

Mode of Action

Miconazole inhibits ergosterol synthesis thus damaging fungal cell wall membrane and increases its permeability, allowing leakage of nutrients.

Precaution

For external use only. Avoid introduction into the eyes.\r\n\r\nLactation: not known whether distributed into milk; use caution\r\n

Side Effect

Irritation,BurningmMaceration,Allergic contact dermatitis\r\nIrritation, burning, maceration, allergic contact dermatitis (all rare)

Interaction

May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\r\n\r\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.